The performance confirms the group's leadership position across all business lines. The most significant advances were recorded in the hospitals division (+39.2%) and clinics (+19.2%), followed by laboratories (+16.1%) and pharmacies (+11.2%). The performance of these divisions confirms the positive impact of recent investments in medical equipment, integrated digital solutions and strategic partnerships with top specialists.

Alongside financial consolidation, the company is accelerating strategic development in personalised medicine through launching Longevity100+, the first and most comprehensive genetic testing programme in the region. Starting next year, genetic testing will be available to the general public at an accessible price, marking a concrete step towards transforming preventive medicine in Romania.

"The results from the first nine months confirm that our growth model is solid and sustainable. The investments we make in technology, automation, genetics and artificial intelligence are not just expenses, but strategic assets that will generate value in the coming years," said Mihai Marcu, President and CEO of MedLife Group. "We are moving from medical screening and treatment services to personalised health plans, based on exact data provided by genetics and our multidisciplinary medical teams."

The group continued expanding medical infrastructure nationally through organic projects. These included inaugurating the new operating theatre at MedLife Craiova Hospital, opening a new medical unit in Pitești with an investment of over €3 million, and launching the first fully automated laboratory in Brașov with an investment of over €2 million.

MedLife is also developing AI solutions for advanced analysis of medical images and data, contributing to diagnostic accuracy and reduced response times for patients.